Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022).

Drug approval enables entry of therapeutic agents into markets, but insurance reimbursement often determines when patients may receive therapy. In this international study (United States, England, Germany, France, Switzerland) examining time from approval to reimbursement, differences in reimbursement processes, and drug coverage were observed. These findings have important policy and safety implications. [ABSTRACT FROM AUTHOR]